SCHEMBL894634

SCHEMBL894634

Cc1ccccc1S(=O)(=O)Nc1cccc(Nc2nc(Cl)ccc2C(N)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
RXFP1 Q9HBX9 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SLC22A12 Q96S37 2/20 0.43
MAPK1 P28482 1/20 0.43
TP53 P04637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SYK P43405 3/20 0.42
HSD17B1 P14061 3/20 0.41
HSD17B2 P37059 3/20 0.41
AURKB Q96GD4 1/20 0.40
PTPN2 P17706 2/20 0.40
PTPN1 P18031 2/20 0.40
PTPN5 P54829 2/20 0.40
JAK2 O60674 1/20 0.40
ROCK2 O75116 1/20 0.40
MAP4K4 O95819 1/20 0.40
HCK P08631 1/20 0.40
ROS1 P08922 1/20 0.40
PIM1 P11309 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2714172 0.80 SYK (0.57) MAPK1SYKAURKBFER
SCHEMBL28994632 0.75 SYK (0.54) ALDH1A1TP53SYKMAPK10
SCHEMBL15888492 0.75 ALDH1A1 (0.54) ALDH1A1SLC22A12MAPK1TP53TDP1
SCHEMBL30283037 0.75 SYK (0.54) ALDH1A1TP53SYKMAPK10
SCHEMBL894635 0.73 HTT (0.47) ALDH1A1L3MBTL1MAPK1LMNA
SCHEMBL9478959 0.73 ALDH1A1 (0.55) ALDH1A1L3MBTL1SLC22A12TP53TDP1
SCHEMBL28270281 0.71 HTR6 (0.62) ALDH1A1SLC22A12TP53TDP1HSD17B1
SCHEMBL893867 0.70 SYK (0.51) SYKJAK2
SCHEMBL17102998 0.70 IDH1 (0.65) IDH1
SCHEMBL5409022 0.69 MAPK13 (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440204-B1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL MYERS SQUIBB CO (US) 2013-12-18 EP disclosed
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
EP-2440204-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS Bristol-Myers Squibb Company (US) 2012-04-18 EP disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
WO-2010144647-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT ALDH1A1 2193/4885RXFP1 4117/4885L3MBTL1 4514/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.